weekli public detail key catalyst come three six month
dollar million except note
event highlight come week
 approv risankizumab moder sever psoriasi
fda advisori committe meet discuss potenti approv even
romosozumab postmenopaus osteoporosi
regulatori develop busi updat
present initi data
clinic regulatori updat
phase result opdivo checkmat overal surviv
result nsclc checkmat
phase robust trial result revlimid frontlin diffus larg b-
cell lymphoma activ b-cell subtyp
data second third three phase studi rheumatoid
arthriti filgotinib
risankizumab key pipelin candid sustain revenu growth humira lose patent exclus
 estim peak sale billion
clinic result even posit efficaci cardiovascular signal creat concern risk/reward
postmenopaus osteoporosi patient lower expect commerci drug
ubrogep nda file migrain open-label mapl studi reformul abicipar wamd bla file
divest women health infectious-diseas franchis on-going loe pressur led restasi
announc posit top-lin result initi clinic trial intrathec deliv antiesens
oligonucleotid patient mutat al data present provid detail safeti efficaci
valrox vosoritid phase trial on-going palynziq fda-approv chmp opinion expect posit
phase ii vosoritid data present day novemb ind pku gene therapi
opdivo combin opdivo plu yervoy studi sever on-going phase trial potenti
expand market opportun therapi
diffus larg b-cell lymphoma market could one materi expans opportun revlimid non-
posit result finch would lead regulatori file project filgotinib gener
billion peak sale
data steroid-refractori gvhd
reach program trial part strategi expand jakafi indic acut chronic gvhd
regulatori develop busi updat
top-lin data phase studi symdeko
fda approv receiv takhzyro lanadelumab montegr prucaloprid billion take-over offer takeda
close pass eu anti-trust decis sharehold vote
success tripl combin potenti address total cf popul crucial long-term
valu vertex share
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report result investor awar firm may conflict interest could affect object report report intend provid person invest advic
opinion recommend herein take account individu client circumst object need intend recommend particular secur financi instrument strategi particular client recipi report must make independ decis
regard secur financi instrument mention herein
mid-cap compani market cap billion billion
top-lin data phase studi zanubrutinib versu imbruvica
quarterli launch progress cabometyx
major advers cardiovascular event mace analysi roxadustat
regulatori clinic updat
first global trial zanubritinib success demonstr superior imbruvica posit
read-through global phase studi serv major driver growth beigen share
lentiglobin accept ema acceler assess decis anticip first half
look forward clinic updat near-term focu among investor like center around
continu progress cabometyx launch
posit efficaci data five phase studi investor focu shift pool mace analysi posit mace
result combin better-than-expect efficaci profil could lead rapid adopt roxadustat
vitraki larotrectinib approv fda price expect annual enrol first patient
updat result combin opdivo
urotheli carcinoma third cohort materi data phase ii studi given phase
studi alreadi plan believ investor would like see data valid strategi
clinic regulatori updat
zulresso pdufa date decemb posit adcom vote risk/benefit profil pivot trial readout
jan pivot phase trial mdd commenc
exondi launch updat exon exon aav develop
phase ii studi top-lin result enfortumab vedotin
platinum- checkpoint inhibitor-relaps urotheli carcinoma
golodirsen nda submit casimersen biopsi data readout pivot microdystrophin gene
therapi trial list biopsi data phase i/ii trial expect gene therapi asset
compani move post-adcetri era enfortumab vedotin repres first mani pipelin asset
could contribut independ adcetri
edsivo clinic trial public regulatori file accept
potenti partnership announc zemdri europ
final readout phase ii add-on switch studi
pnh patient sub-optimal respons soliri
final readout phase ii add-on switch studi
pnh patient sub-optimal respons soliri second half
gocovri launch pipelin regulatori updat
initi clinic data patient multipl myeloma
addit data plu spartalizumab
detail next-gener cancer immunotherapi includ bispecif
cell therapi subsidiari agentu
regulatori meet disput resolut
preregistr studi discuss fda
aml md
public pari registri studi celiprolol edsivo ved expect immin edsivo nda submit request
acceler approv develop commenc
compani also submit ema august decis expect within month submiss
depend partnership
posit data would valid mechan factor inhibit treatment pnh data packag
could lead registr suffici posit
eskata dtc launch top-lin phase ii trial data topic alopecia areata posit open-label trial
gocovri launch on-going phase trial ms gait initi endofphas ii meet fda
partial onset seizur conduct posit feedback
follow initi monotherapi data investor need see signific synergi antibodi
spartalizumab increas confid develop biomark data may show activ
secur addit capit partnership gilead continu advanc wholli own asset
includ plu combin cervic cancer
twirla receiv cite issu ond recommend conduct twirla adhes studi compar xulan gener
ortho evra patch expect commenc prior discuss efficaci review
data r/r r/r aml/md compani determin phase ii trial design
top-lin data phase studi
final data phase ii studi evalu nuke interferon
updat program
top-lin data phase iia program nuke chronic
phase result tabelecleucel ptld
data phase i/ii studi multistem ard
phase studi serv singl pivot trial potenti eu approv
open-label trial expect read chronic spontan urticaria indol system mastocytosi
allerg conjunct phase ii trial eosinophil gastritis/gastroenter read
result may provid preliminari indic whether tripl combin could suffici increas function
posit data early-stag program ascrib addit valu compani could justifi exclus
licens lead asset aro-hbv
posit result stage would provid first signal combo util help establish cpam class key
compon potenti hbv cure regimen
atara run two phase trial tabelecleucel patient ptld follow stem cell solid organ transplant
posit result lead compani first regulatori approv file
success studi would give confid likelihood success phase treasur
interim data phase ib/iia studi pulmonari
posit interim result phase i/ii studi would give confid overal success trial
interim data dose escal studi adult
addit data dlbcl
belbuca weekli script launch canada polit regulatori
implic opioid crisi
clinic trial regulatori updat
initi efficaci data arginas inhibitor
develop collabor incyt
data phase adapt trial oral brincidofovir pediatr
xtampza er weekli script nucynta sale launch polit regulatori
implic opioid crisi
data phase ii trial treatment aureu
bacteremia includ mrsa endocard
potenti initi phase studi melanoma hnscc sd-
regulatori clinic intellectu properti updat
regulatori clinic updat
phase forward studi result mirvetuximab soravtansin
matur data studi opdivo
rmat design grant biopsi data show impress benefit trial proce next dose
data updat expect
autolu continu provid updat on-going clinic program dose escal studi includ
first half later
on-going belbuca commerci canada launch purdu sale market access forc expans high-
speed manufactur place express script pbm coverag secur
fast-act rimegep phase trial long-term safeti posit ahead nda file episod migrain
phase ii/iii trial readout troriluzol ocd alzheim diseas interim futil expect
follow failur ido inhibitor epacadostat investor expect arginas inhibit
mute posit clinic data first half could chang sentiment
updat data think revis dose regimen first half deplethink aml expect alloshrink
data expect second half
studi like last shot oral formul brincidofovir posit result could lead condit full eu
approv potenti file unit state
on-going market campaign new abuse-deterr claim label xtampza er new exclus payer contract
kick januari strateg review on-going near- midterm bd opportun
trial result could provid first proof-of-concept data human pave way pivot studi
depend type partnership cost-shar exclus licens deal compani expect initi
keytruda melanoma and/or hnscc
bendamustin big bag approv launch bendeka royalti protect decemb vasopressin
inject anda review first file fda clariti tent approv treanda gener expect immin
data regulatori updat exceed expect pre-nda meet public part patient part
 complet expect first half
posit result could valid strateg initi execut compani focus mirvetuximab soravtansin
also favor read combin studi
emerg profil phase studi dictat magnitud valu creation next month
could lead phase ii studi initi beyond bladder cancer
result phase ib dose escal trial patient
system lupu erythematosu lupu nephriti
interim data phase ii studi acelarin platinum-
clinic trial updat initi
logicbio recent announc next-gener aav collabor children medic research institut mma natur
histori studi initi second pipelin indic nomin expect near term
initi safeti efficaci data patient lupu provid proof concept increas investor
confid lupu autoimmun diseas
dose phase ii studi complet inlcud four pediatr patient top-lin result expect
ind expect year end
pend posit data manag meet fda discuss potenti acceler approv pathway acelarin
indic
move pivot phase neptun trial phase ib/iia trial demonstr seizur reduct
phase ii elektra arcad trial on-going phase ii rocket studi fragil read
fda accept new drug applic via
view fda file data packag start review clock suggest applic complet could
also impli transit clinic suppli commerci suppli met agenc standard
result phase dose escal studi phase iia
studi patient function iron defici
fda approv manufactur pa andexxa
clinic trial initi updat manag chang
clinic trial initi updat
proof-of-concept result show local t-cell activ compani lead bispecif therapi would increas
interest program posit result could lead licens agreement up-front payment
portola submit pa manufactur andexxa approv would allow suppli expand
hospit unit state
complet acquisit ad gene therapi platform akcea collabor potenti
commerci two product translarna dystrophin studi initi year-end
pkan phase fort top-lin data fsg phase duplex trial on-going phase protect trial sparsentan
igan commenc top-lin phase ii data pku expect
cervic dystonia phase aspen trial on-going revis phase ii plantar fasciiti trial phase ii limb spastic program
commenc phase safeti trial posit bla submiss track glabellar line
initi phase trial first aav-bas therapi danon diseas initi phase i/ii trial rp-
fanconi anemia grant rmat fast track design fda
clinic regulatori updat
commerci clinic updat
luxturna eu launch complet phase i/ii updat expect
gilead report interim data phase ii studi inarigivir vemlidi
data phase iib trial ibs-c
announc phase iib biopsy-confirm nash studi design
clinic regulatori updat
synergi nuke show higher efficaci nuke monotherapi bode well combin therapi phase
trial potenti futur partnership gilead
result suffici posit differenti compani plan select dose enter partnership
discuss potenti phase studi commerci ibs-c
upon complet anim toxic studi vike plan submit ind random studi biopsy-
confirm nash given uncertainti data investor pay close attent readout
long-term safeti data dravet syndrom cardio-clean complet roll nda phase
trial lg commenc ex-u enrol expect read phase interact trial
